Allogeneic T-Cell Therapy for Autoimmune Diseases Market

DelveInsight’s “Allogeneic T-Cell Therapy for Autoimmune Diseases – Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the allogeneic T-cell therapy for autoimmune diseases, historical and forecasted epidemiology as well as the allogeneic T-cell therapy for autoimmune diseases market trends in the United States, EU4 (Germany, France, Italy, Spain) and United Kingdom, and Japan.

 

The allogeneic T-cell therapy for autoimmune diseases market report provides current treatment practices, emerging drugs, allogeneic T-cell therapy for autoimmune diseases market share of the individual therapies, and current and forecasted allogeneic T-cell therapy for autoimmune diseases market size from 2019 to 2032, segmented by seven major markets. The report also covers current allogeneic T-cell therapy for autoimmune diseases treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, Spain) and United Kingdom
• Japan

 

Study period: 2019–2032

 

Allogeneic T-cell therapy for autoimmune diseases Understanding and Treatment Algorithm

The DelveInsight’s allogeneic T-cell therapy for autoimmune diseases market report gives a thorough understanding of allogeneic T-cell therapy for autoimmune diseases by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. More than 80 diseases occur as a result of the immune system attacking the body’s own organs, tissues, and cells. Some of the more common autoimmune diseases include type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease. Although the causes of many autoimmune diseases remain unknown, a person’s genes in combination with infections and other environmental exposures are likely to play a significant role in disease development.

 

T lymphocytes play a central role in regulation of the immune system. Both effector and regulatory T cells work in equilibrium to provide optimal immune response against foreign pathogens. T cells, in particular CD4+ T cells, have been implicated in mediating many aspects of autoimmune inflammation. Moreover, the regulatory T cells (Tregs), specifically CD4+CD25+Foxp3+ Tregs, exert a tight control over autoreactive B and T cell responses in the periphery.

 

 Allogeneic T-cell therapy for autoimmune diseases diagnosis

Allogeneic T-cell therapy for autoimmune diseases is diagnosed based on detailed patient history, thorough clinical evaluation, and a variety of tests, including a biopsy of an affected lymph node or the bone marrow, blood tests, and imaging tests.

 

Allogeneic T-cell therapy for autoimmune diseases treatment

Engineered T-cell therapies using chimeric antigen receptors (CARs) against CD19+ B cell malignancies are changing the clinical practices. Earlier treatment of autoimmune disorders focused on managing end-organ manifestations such as insulin replacement in diabetes and alleviating pain and inflammation in arthritis. The current standard of care includes non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids and disease-modifying anti-rheumatic drugs (DMARDs). NSAIDs and glucocorticoids reduce inflammation and alleviate pain, while DMARDs are effective in reducing the damaging effect of the inflammatory autoimmune response.

 

Allogeneic T-cell Therapy for Autoimmune Diseases Epidemiology

The allogeneic T-cell therapy for autoimmune diseases epidemiology section provides insights into historical and current allogeneic T-cell therapy for autoimmune diseases patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the allogeneic T-cell therapy for autoimmune diseases report also provides the diagnosed patient pool, their trends and assumptions undertaken.

 

Key findings

As per Aghajanian H (2022), In Europe there were more than 600,000 allogeneic T-cell therapy for autoimmune diseases patients estimated, with a median prevalence of 100 cases and a median incidence of 5.5 cases per 100,000.

 

The allogeneic T-cell therapy for autoimmune diseases epidemiology covered in the report provides historical as well as forecasted allogeneic T-cell therapy for autoimmune diseases epidemiology [segmented as Total Prevalent Cases of Potential Autoimmune Indications for Allogeneic T-Cell Therapy, Total Diagnosed Prevalent Cases of Selected Indications, Total Indication wise eligible cases, and Indication wise Treatable Cases with Allogenic T-cell Therapy] in the 7MM covering the United States, EU4 (Germany, France, Italy, Spain) and United Kingdom, and Japan from 2019 to 2032.

 

Country-wise Allogeneic T-cell Therapy for Autoimmune Diseases Epidemiology

The epidemiology segment also provides the allogeneic T-cell therapy for autoimmune diseases epidemiology data and findings across the United States, EU4 (Germany, France, Italy, Spain) and United Kingdom, and Japan.

 

Allogeneic T-cell Therapy for Autoimmune Diseases Drug Chapters

The drug chapter segment of the allogeneic T-cell therapy for autoimmune diseases report encloses the detailed analysis of allogeneic T-cell therapy for autoimmune diseases marketed drugs and late-stage (Phase III and Phase II) allogeneic T-cell therapy for autoimmune diseases pipeline drugs. It also helps understand the allogeneic T-cell therapy for autoimmune diseases clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

The report details the emerging allogeneic T-cell therapy for autoimmune diseases therapies under the late and mid-stage of development for allogeneic T-cell therapy for autoimmune diseases treatment.

 

Allogeneic T-Cell Therapy for Autoimmune Diseases Emerging Drugs

ATA188: Atara Biotherapeutics

ATA188 is an off-the-shelf, allogeneic EBV (Epstein-Barr virus) T cell that utilizes a targeted antigen recognition technology that enables the T cells to be administered to selectively identify cells expressing the EBV antigens that may be important in the pathophysiology of Multiple Sclerosis (MS). ATA188 has the potential to target EBV-infected B cells and plasma cells in the central nervous system that may catalyze autoimmune responses and MS pathophysiology. Atara is currently enrolling EMBOLD, a Phase II clinical study of ATA188 in the treatment of patients with progressive forms of MS, across clinical sites in North America and Australia.

 

KYV-201: Kyverna

KYV-201 is a next-generation CAR T construct targeting CD19 for use in allogeneic cell therapies for B-cell driven autoimmune diseases. KYV-201 use a fully human anti-CD19 CAR and costimulatory domains designed to minimize cytokine production. In January 2022 Kyverna entered into an agreement with Intellia.  This agreement granted Kyverna rights to use Intellia’s proprietary ex vivo CRISPR/Cas9-based allogeneic platform for the development of KYV-201 for the treatment of select autoimmune diseases.

Note: Detailed emerging therapies assessment will be provided in the full report of allogeneic T-cell therapy for autoimmune diseases

 

 Allogeneic T-cell Therapy for Autoimmune Diseases Market Outlook

The allogeneic T-cell therapy for autoimmune diseases market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted allogeneic T-cell therapy for autoimmune diseases market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

 

This segment gives a thorough detail of the allogeneic T-cell therapy for autoimmune diseases market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

Key players such as Atara Biotherapeutics and Kyverna along with few others are involved in developing therapies for allogeneic T-cell therapy for autoimmune diseases.

 

According to DelveInsight, the allogeneic T-cell therapy for autoimmune diseases market in 7MM is expected to witness a major change in the study period 2019–2032.

 

Key findings

This section includes a glimpse of the allogeneic T-cell therapy for autoimmune diseases market in 7MM.

 

The United States: Allogeneic T-cell therapy for autoimmune diseases Market Outlook

This section provides the total allogeneic T-cell therapy for autoimmune diseases market size and market size by therapies in the United States.

 

EU4 and the UK: Allogeneic T-cell therapy for autoimmune diseases Market Outlook

The total allogeneic T-cell therapy for autoimmune diseases market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan: Allogeneic T-cell therapy for autoimmune diseases Market Outlook

The total allogeneic T-cell therapy for autoimmune diseases market size and market size by therapies in Japan is also mentioned.

 

Analyst Commentary

• The pipeline of allogeneic T-cell therapy for autoimmune diseases is very robust, many potential therapies are being investigated for the treatment of allogeneic T-cell therapy for autoimmune diseases, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.
• The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate, are likely to boost the growth of the allogeneic T-cell therapy for autoimmune diseases market in the 7MM. Aside from that, the market size of allogeneic T-cell therapy for autoimmune diseases may flourish due to increased research and development, label-expansion of approved therapies into other epilepsy in this field.
• The market growth of allogeneic T-cell therapy for autoimmune diseases may offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists.

 

Allogeneic T-cell Therapy for Autoimmune Diseases Drug Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the allogeneic T-cell therapy for autoimmune diseases market or expected to get launched in the market during the study period 2019–2032. The analysis covers allogeneic T-cell therapy for autoimmune diseases market uptake by drugs, patient uptake by therapies, and sales of each drug. 

This will help in understanding the allogeneic T-cell therapy for autoimmune diseases drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

 

Allogeneic T-cell Therapy for Autoimmune Diseases Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses allogeneic T-cell therapy for autoimmune diseases’ key players involved in developing targeted therapeutics.

 

 Allogeneic T-cell therapy for autoimmune diseases market clinical trial development activities

The report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information for allogeneic T-cell therapy for autoimmune diseases emerging therapies.

 

Allogeneic T-cell Therapy for Autoimmune Diseases Reimbursement Scenario

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

 

KOL Views

To keep up with current epidemiology and market trends, we take KOLs and SMEs' opinions working in the allogeneic T-cell therapy for autoimmune diseases domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns along with allogeneic T-cell therapy for autoimmune diseases market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

 

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the allogeneic T-cell therapy for autoimmune diseases market by using various competitive intelligence tools that include – SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

 

Scope of the Report

• Descriptive overview of allogeneic T-cell therapy for autoimmune diseases, disease overview, patient journeys, treatment algorithms, diagnosis, and currently available therapies
• Comprehensive insight into the allogeneic T-cell therapy for autoimmune diseases epidemiology and forecasts in the 7MM
• An all-inclusive account of both the current and emerging therapies for allogeneic T-cell therapy for autoimmune diseases, along with the assessment of new therapies, expected to have an impact on the current treatment landscape
• Exhaustive analysis of the allogeneic T-cell therapy for autoimmune diseases market; historical and forecasted covering drug outreach in the 7MM
• Trends shaping and driving the global allogeneic T-cell therapy for autoimmune diseases market

 

Report Highlights

• In the coming years, the allogeneic T-cell therapy for autoimmune diseases market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence allogeneic T-cell therapy for autoimmune diseases R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition  
• Major players are involved in developing allogeneic T-cell therapy for autoimmune diseases therapies. The launch of emerging therapies will significantly impact the allogeneic T-cell therapy for autoimmune diseases market
• A better understanding of allogeneic T-cell therapy for autoimmune diseases pathogenesis will also contribute to the development of novel therapeutics for allogeneic T-cell therapy for autoimmune diseases
• Our in-depth analysis of the allogeneic T-cell therapy for autoimmune diseases pipeline assets across different stages of development (Phase III and Phase II), emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Allogeneic T-cell Therapy for Autoimmune Diseases Report Insights

• Patient population
• Therapeutic approaches
• Allogeneic T-cell therapy for autoimmune diseases pipeline analysis
• Allogeneic T-cell therapy for autoimmune diseases market size and trends
• Allogeneic T-cell therapy for autoimmune diseases market opportunities
• Impact of upcoming therapies

 

Allogeneic T-cell Therapy for Autoimmune Diseases Report Key Strengths

• 11 years forecast
• 7MM coverage
• Allogeneic T-cell therapy for autoimmune diseases epidemiology segmentation
• Key cross competition
• KOL views
• Allogeneic T-cell therapy for autoimmune diseases drugs uptake

 

Allogeneic T-cell Therapy for Autoimmune Diseases Report Assessment

• Current treatment practices
• Unmet needs
• Allogeneic T-cell therapy for autoimmune diseases pipeline product profiles
• Allogeneic T-cell therapy for autoimmune diseases market attractiveness

 

Key Questions

Allogeneic T-cell Therapy for Autoimmune Diseases Market Insights:

• What would be the allogeneic T-cell therapy for autoimmune diseases market growth till 2032, and what will be the resultant market size in 2032?
• What was the allogeneic T-cell therapy for autoimmune diseases drug class share (in percentage) distribution in 2019, and how would it look in 2032?
• What would be the allogeneic T-cell therapy for autoimmune diseases total market size and market size by therapies across the 7MM during the forecast period (2019–2032)?
• What are the key findings of the market across 7MM, and which country will have the largest allogeneic T-cell therapy for autoimmune diseases market size during the forecast period (2019–2032)
• How would the unmet needs affect the allogeneic T-cell therapy for autoimmune diseases market dynamics and subsequent analysis of the associated trends?

 

Allogeneic T-cell Therapy for Autoimmune Diseases Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of allogeneic T-cell therapy for autoimmune diseases?
• What is the historical and forecasted allogeneic T-cell therapy for autoimmune diseases patient pool in 7MM, and where can one observe the highest patient population and growth opportunities?
• What are the key factors driving the epidemiology trends for seven major markets covering the United States, EU4 (Germany, France, Italy, Spain) and United Kingdom, and Japan?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current treatment guidelines and treatment options, in addition to approved therapies for Allogeneic T-cell therapy for autoimmune diseases in the US, Europe, and Japan?
• What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to allogeneic T-cell therapy for autoimmune diseases therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for allogeneic T-cell therapy for autoimmune diseases and its status, along with the challenges faced?

 

Reasons to Buy

• The report will help in developing business strategies by understanding trends shaping and driving the allogeneic T-cell therapy for autoimmune diseases market
• Organize sales and marketing efforts by identifying the best opportunities for allogeneic T-cell therapy for autoimmune diseases in the US, EU4 (Germany, France, Italy, Spain) and UK, and Japan
• Identification of strong upcoming players in the market that will help devise strategies that will help in getting ahead of competitors